Related Experiment Video
Updated: May 29, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
[Neoadjuvant therapy before radical prostatectomy - indications and protocols].
Michael Lamche1, Paul Schramek
1Abteilung für Urologie und Andrologie, Krankenhaus der Barmherzigen Brüder, Wien, Austria. michael.lamche@bbwien.at
Wiener Medizinische Wochenschrift (1946)
|September 29, 2011
Summary
Neoadjuvant hormone ablation shows promise for hormone-sensitive prostate cancer, potentially treating early disease and improving local control. High-quality studies are needed to confirm its role in prostate cancer treatment.
Area of Science:
- Oncology
- Urology
Background:
- Neoadjuvant chemotherapy is standard for many nonorgan-confined malignancies.
- Neoadjuvant hormone ablation is emerging as a promising treatment for hormone-sensitive prostate cancer.
Observation:
- Neoadjuvant therapy offers early systemic treatment for subclinical metastatic disease.
- It aims to enhance local disease control and downstage tumors.
- This can increase eligibility for definitive local therapies.
Findings:
- Limited and heterogeneous studies currently exist on neoadjuvant hormone ablation for prostate cancer.
- Encouraging preliminary results have been reported.
Implications:
- Prospective, high-quality studies are essential to evaluate the definitive role of neoadjuvant hormone ablation.
- Further research will clarify its potential in improving outcomes for prostate cancer patients.
